Researchers designed a bispecific T cell engager capable of cross-linking CD3 on T cells with NKG2DL-expressing GBM cells. They then engineered the G207 virus to express the NKG2D BiTE and secrete it from infected cells.
[Journal For Immunotherapy Of Cancer]